TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$5.71 +0.03 (+0.53%) (As of 07/26/2024 ET) Add Compare Share Share Today's RangeC$5.65▼C$5.7250-Day RangeC$5.41▼C$6.1152-Week RangeC$4.35▼C$6.22Volume27,194 shsAverage Volume65,499 shsMarket CapitalizationC$578.88 millionP/E RatioN/ADividend YieldN/APrice TargetC$6.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Knight Therapeutics alerts: Email Address Knight Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside18.2% UpsideC$6.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling SharesC$526,782 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 stars 2.3 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Knight Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GUD. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GUD. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for GUD on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have sold 1,716.49% more of their company's stock than they have bought. Specifically, they have bought C$29,000.00 in company stock and sold C$526,782.00 in company stock.Percentage Held by Insiders46.36% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.68% of the stock of Knight Therapeutics is held by institutions.Read more about Knight Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -35.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -35.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Knight Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Knight Therapeutics Stock (TSE:GUD)Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Read More GUD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUD Stock News HeadlinesJuly 4, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 10,000 SharesJuly 24 at 6:24 AM | finance.yahoo.comKnight Therapeutics Inc. (KHTRF)July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 15, 2024 | seekingalpha.comGUD:CA Knight Therapeutics Inc.May 12, 2024 | seekingalpha.comKnight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call TranscriptApril 21, 2024 | investing.comKnight Therapeutics Inc (GUD)April 16, 2024 | msn.comTSX Healthcare in April 2024: The Best Stocks to Buy Right NowApril 9, 2024 | finance.yahoo.comKnight to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.March 23, 2024 | investing.comEarnings call: Knight Therapeutics announced record revenues of $343 millionMarch 22, 2024 | finance.yahoo.comKnight Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 20, 2024 | ca.finance.yahoo.comKnight Therapeutics Inc (04K.SG)March 14, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.March 7, 2024 | finance.yahoo.comFavourable Signals For Knight Therapeutics: Numerous Insiders Acquired StockFebruary 29, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.,February 29, 2024 | msn.comKnight Therapeutics launches Minjuvi in BrazilFebruary 21, 2024 | finance.yahoo.comKnight Therapeutics Announces Regulatory Submission of Fostamatinib in BrazilJanuary 4, 2024 | finance.yahoo.comKnight Therapeutics Announces Product Launch for IMVEXXY® in CanadaSee More Headlines Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Stock Price TargetC$6.75 High Stock Price TargetC$7.50 Low Stock Price TargetC$5.75 Potential Upside/Downside+18.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.16) Trailing P/E RatioN/A Forward P/E Ratio188.17 P/E Growth-1013.5Net IncomeC$-17,440,000.00 Net Margins-5.25% Pretax MarginN/A Return on Equity-2.21% Return on Assets0.21% Debt Debt-to-Equity Ratio9.20 Current Ratio3.34 Quick Ratio1.79 Sales & Book Value Annual SalesC$332.21 million Price / Sales1.74 Cash FlowC$1.48 per share Price / Cash Flow3.85 Book ValueC$7.53 per share Price / Book0.76Miscellaneous Outstanding Shares101,380,000Free FloatN/AMarket CapC$578.88 million OptionableNot Optionable Beta0.46 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Comp: $250.94kMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Comp: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human ResourcesMore ExecutivesKey CompetitorsTilray BrandsTSE:TLRYCronos GroupTSE:CRONHydropothecaryCVE:THCXCanopy GrowthTSE:WEEDAurora CannabisTSE:ACBView All CompetitorsInsidersAmal KhouriSold 10,000 sharesTotal: C$57,000.00 ($5.70/share)Amal KhouriSold 10,000 sharesTotal: C$57,200.00 ($5.72/share)Amal KhouriSold 20,000 sharesTotal: C$116,022.00 ($5.80/share)Jonathan Ross GoodmanBought 5,000 shares on 6/5/2024Total: C$29,000.00 ($5.80/share)Robert Nathaniel LandeSold 15,000 sharesTotal: C$88,600.50 ($5.91/share)View All Insider Transactions GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$5.19 at the beginning of 2024. Since then, GUD stock has increased by 10.0% and is now trading at C$5.71. View the best growth stocks for 2024 here. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.06. The company had revenue of $86.60 million for the quarter, compared to the consensus estimate of $80.27 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 2.21% and a negative net margin of 5.25%. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B) and Chemtrade Logistics Income Fund (CHE.UN). This page (TSE:GUD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GUD Stock Alerts